Background Pulmonary hypertension (PH) is a common disorder in patients with idiopathic
pulmonary fibrosis (IPF) and portends a poor prognosis. Recent studies using vasodilators …

Fibrosing lung disorders include a large number of diseases with diverse behaviour.
Patients can die because of the progression of their illness, remain stable or even improve …

Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD)
patients resulting in poor functional status and worse outcomes. Early recognition of PH in …

Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple
comorbidities, which may influence survival but go under-recognised in clinical practice. We …

Abstract Background Pulmonary Langerhans cell histiocytosis (PLCH) is a rare interstitial
disease affecting primarily young adult smokers. In order to highlight the clinical features of …

Nintedanib (Ofev™), an oral triple kinase inhibitor targeting pro-fibrotic pathways, has been
used for treatment of idiopathic pulmonary fibrosis (IPF). Based on positive results from …

Diagnosing pulmonary sarcoidosis raises challenges due to both the absence of a specific
diagnostic criterion and the varied presentations capable of mimicking many other …

Background: Two therapeutic options are currently available for patients with mild-to-
moderate idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. To date, there is …

Chronic hypersensitivity pneumonitis is a common fibrotic interstitial lung disease. The
prevalence of pulmonary hypertension diagnosed by right heart catheterisation and its …

Breathlessness is a common symptom in pulmonary hypertension (PH) and an important
cause of morbidity. Though this has been attributed to the well described pulmonary …